- Home
- CLNN vs MRSN Comparison
CLNN vs MRSN Comparison
Compare CLNN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLNN | MRSN |
|---|---|---|
| Founded | 2012 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 138.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLNN | MRSN |
|---|---|---|
| Price | $5.72 | $27.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $32.67 | $30.38 |
| AVG Volume (30 Days) | ★ 290.7K | 236.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $214,000.00 | ★ $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $87.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.28 | $5.21 |
| 52 Week High | $13.50 | $70.73 |
Technical Indicators
Market Signals| Indicator | CLNN | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 83.68 |
| Support Level | $8.90 | $27.31 |
| Resistance Level | $9.92 | $28.36 |
| Average True Range (ATR) | 1.03 | 0.52 |
| MACD | -0.40 | -0.26 |
| Stochastic Oscillator | 2.12 | 51.65 |
Price Performance
Historical ComparisonAbout CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.